Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.
Orforglipron treatment was associated with improvements in physical and psychosocial functioning in adults with obesity, particularly in those with higher baseline BMI and physical limitations.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This study evaluated the effects of orforglipron on physical and psychosocial functioning in adults with obesity over 72 weeks. The analysis included patient-reported outcomes from the ATTAIN phase 3 trials. Improvements were noted in health-related quality of life and physical function compared to placebo.
Abstract
<h4>Background</h4>In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes.<h4>Methods</h4>This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m<sup>2</sup>, ≥35 to <40 kg/m<sup>2</sup>, and ≥40 kg/m<sup>2</sup>) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates.<h4>Results</h4>Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements.<h4>Conclusion</h4>Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.<b>ATTAIN-1: NCT05869903; ATTAIN-2:</b>NCT05872620.
Background
This paper addresses the impact of orforglipron on physical and psychosocial functioning in adults with obesity, a population that often experiences impaired quality of life. Prior studies have indicated that weight reduction can lead to improvements in health-related quality of life, but specific outcomes related to orforglipron had not been thoroughly evaluated. This study is significant as it explores patient-reported outcomes in the context of a phase 3 trial.
Methods
The study involved prespecified secondary and post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials, which were phase 3, randomized, placebo-controlled trials. The population included adults with obesity, and the outcomes were assessed using various validated questionnaires over a duration of 72 weeks. The primary focus was on health-related quality of life and physical functioning as measured by multiple PRO instruments.
Results
Participants receiving orforglipron demonstrated greater improvements in PROs compared to placebo, particularly in physical function. However, specific numeric findings, including effect sizes and p-values, were not reported in the abstract. The exploratory subgroup analyses suggested that individuals with higher baseline BMI and those with physical function limitations experienced more significant improvements.
Interpretation
The findings suggest that orforglipron may positively influence health-related quality of life and physical functioning in individuals with obesity, aligning with previous literature on weight loss and quality of life. However, the lack of detailed numeric outcomes limits the ability to assess the clinical significance of these improvements. Additionally, the reliance on post-hoc analyses raises concerns about the robustness of the conclusions.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Post-hoc analyses may limit the robustness of the findings.
- Sample sizes for specific outcomes were not provided.
- No specific numeric outcomes or effect sizes reported.